A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation

NCT Number	NCT07752875
Lead Sponsor	LG Chem
Conditions	Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer +2 more
Enrollment	250 participants
Start Date	2026-12-01
Primary Completion	2032-10-31 (estimated)
Study Completion	2033-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-07